Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanc...
Craig R. Nichols, MD, of the Testicular Cancer Commons and the SWOG Group Chair's Office, discusses the superior outcomes obtained at high-volume centers, the impracticality ...
Sumit K. Subudhi, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the initial results from a phase II study of nivolumab plus ipilimumab in the treat...